MK-7962 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	10

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05587712 (ClinicalTrials.gov)	January 19, 2023	17/10/2022	Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7 ...	A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam ...	Pulmonary Arterial Hypertension	Drug: Sotatercept	Merck Sharp & Dohme LLC	NULL	Recruiting	1 Year	17 Years	All	42	Phase 2	United States
2	EUCTR2022-000478-25-ES (EUCTR)	23/12/2022	13/10/2022	Sotatercept in Children with Pulmonary Artery Hypertension on Standard of Care	A Phase 2 Open-label Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Pharmacodynami ...	Pulmonary arterial hypertension MedDRA version: 21.1;Level: LLT;Classification code 10037403;Term: P ...	Product Name: Sotatercept Product Code: MK-7962 INN or Proposed INN: Sotatercept	Merck Sharp & Dohme LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	42	Phase 2	United States;Spain;Turkey;Israel;Colombia;United Kingdom;France;Mexico;Poland;Australia;South Afric ...
3	EUCTR2020-005061-13-AT (EUCTR)	05/05/2022	02/12/2021	A Long-term Follow-up Study of Sotatercept for PAH Treatment	An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Backgro ...	Pulmonary Arterial Hypertension (PAH) MedDRA version: 21.1;Level: PT;Classification code 10064911;Te ...	Product Name: Sotatercept - 60 mg/vial Product Code: ACE-011/ MK-7962 INN or Proposed INN: SOTATERCEPT ...	Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	700	Phase 3	Serbia;Portugal;United States;Taiwan;Greece;Spain;Israel;Colombia;Switzerland;Italy;France;Australia ...
4	NCT04811092 (ClinicalTrials.gov)	March 18, 2022	16/3/2021	Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A0 ...	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to ...	Pulmonary Arterial Hypertension	Drug: Sotatercept;Other: Placebo	Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & C ...	NULL	Recruiting	18 Years	N/A	All	662	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czechia;Denmark;Fra ...
5	EUCTR2020-005061-13-BE (EUCTR)	07/03/2022	26/11/2021	A Long-term Follow-up Study of Sotatercept for PAH Treatment	An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Backgro ...	Pulmonary Arterial Hypertension (PAH) MedDRA version: 21.1;Level: PT;Classification code 10064911;Te ...	Product Name: Sotatercept - 60 mg/vial Product Code: ACE-011 / MK-7962 INN or Proposed INN: SOTATERCEP ...	Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	700	Phase 3	Serbia;Portugal;United States;Taiwan;Greece;Israel;Colombia;Switzerland;Italy;France;Australia;Denma ...
6	EUCTR2020-005061-13-CZ (EUCTR)	02/03/2022	20/12/2021	A Long-term Follow-up Study of Sotatercept for PAH Treatment	An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Backgro ...	Pulmonary Arterial Hypertension (PAH) MedDRA version: 21.1;Level: PT;Classification code 10064911;Te ...	Product Name: Sotatercept - 60 mg/vial Product Code: ACE-011 / MK - 7962 INN or Proposed INN: SOTATERC ...	Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	700	Phase 3	Serbia;Portugal;United States;Taiwan;Greece;Spain;Israel;Colombia;Switzerland;Italy;France;Denmark;A ...
7	EUCTR2020-005061-13-PL (EUCTR)	26/01/2022	02/12/2021	A Long-term Follow-up Study of Sotatercept for PAH Treatment	An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Backgro ...	Pulmonary Arterial Hypertension (PAH) MedDRA version: 21.1;Level: PT;Classification code 10064911;Te ...	Product Name: Sotatercept - 60 mg/vial Product Code: ACE-011/ MK-7962 INN or Proposed INN: SOTATERCEPT ...	Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	700	Phase 3	United States;Czechia;Portugal;Greece;Austria;Sweden;Netherlands;Poland;Brazil;Korea, Republic of;Fr ...
8	NCT04896008 (ClinicalTrials.gov)	December 1, 2021	13/5/2021	A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-79 ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to ...	Pulmonary Arterial Hypertension	Drug: Sotatercept;Other: Placebo	Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & C ...	NULL	Recruiting	18 Years	75 Years	All	200	Phase 3	United States;Australia;Belgium;Canada;France;Germany;Israel;Italy;Mexico;Netherlands;Spain;United K ...
9	NCT04796337 (ClinicalTrials.gov)	May 12, 2021	22/2/2021	A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004)	An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Backgro ...	Pulmonary Arterial Hypertension;PAH	Biological: Sotatercept	Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & C ...	NULL	Recruiting	18 Years	N/A	All	700	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czechia;Denmark;Fra ...
10	NCT04576988 (ClinicalTrials.gov)	January 25, 2021	28/9/2020	A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(ST ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of ...	Pulmonary Arterial Hypertension	Biological: Sotatercept;Drug: Placebo;Drug: Background PAH Therapy	Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & C ...	NULL	Completed	18 Years	N/A	All	324	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;France;Germany;Israel;Italy;Korea, R ...

First Previous1Next Last